With the rapid increase in new therapies to treat advanced prostate cancer, improved diagnosis tools are necessary to help refine patient management throughout the entire disease course. Many radiopharmaceuticals, most of which are imaged using positron emission tomography/computed tomography (PET/CT), are in development; two of these newer radiopharmaceuticals are (1)(8)F-sodium fluoride (NaF) and radiolabeled choline. Compared with traditional imaging, use (1)(8)F-NaF has been shown to improve sensitivity and specificity, and radiolabeled choline has been shown to detect recurrent and metastatic disease earlier. We briefly review these two imaging technologies and provide potential utilization strategies based on available data.
Mendeley saves you time finding and organizing research
Choose a citation style from the tabs below